The Treatment Combining Antiangiogenesis with Chemoradiotherapy Impinges on the Peripheral Circulation Vascular Endothelial Cells and Therapeutic Effect in the Patients with Locally Advanced Nasopharyngeal Carcinoma
- PMID: 35872851
- PMCID: PMC9307343
- DOI: 10.1155/2022/1787854
The Treatment Combining Antiangiogenesis with Chemoradiotherapy Impinges on the Peripheral Circulation Vascular Endothelial Cells and Therapeutic Effect in the Patients with Locally Advanced Nasopharyngeal Carcinoma
Retraction in
-
Retracted: The Treatment Combining Antiangiogenesis with Chemoradiotherapy Impinges on the Peripheral Circulation Vascular Endothelial Cells and Therapeutic Effect in the Patients with Locally Advanced Nasopharyngeal Carcinoma.Biomed Res Int. 2024 Mar 20;2024:9842547. doi: 10.1155/2024/9842547. eCollection 2024. Biomed Res Int. 2024. PMID: 38550099 Free PMC article.
Abstract
This study was implemented for the evaluation on the circulating endothelial cells' (CECs) clinical significance in the locally advanced nasopharyngeal carcinoma treatment with endostatin-combined chemoradiotherapy. This study enrolled 47 patients with locally advanced nasopharyngeal carcinoma who were hospitalized from May 9, 2012 to March 10, 2013. These patients were split up into the observation group (25 patients) and control group (22 patients). Patients in the observation group received the endostatin combined with induction chemotherapy and subsequently with concurrent chemoradiotherapy with endostatin. Patients in the control group were treated with inductive chemotherapy followed by concurrent chemoradiotherapy. CECs in peripheral blood were conducted separately before or after inductive chemotherapy and additionally in the end of concurrent chemoradiotherapy. The CEC values of the observation group showed significant statistical differences (p < 0.05) before or after different therapies, whereas those data in the control group were not statistically different. And, the mostly importantly, the CEC values in the observation group and control group turned out a statistical difference. The combination of endostatin and chemoradiotherapy significantly reduced parameters of peripheral blood CECs in these patients. According to the CEC parameters' variety that we observed in the combined therapies, this study demonstrated that the CECs might be a clinical clue to evaluate this antiangiogenic chemoradiotherapy. And the clinical value of CECs will be further determined along with increasing comparative studies and clinical long-term efficacy observation.
Copyright © 2022 Xiuyun Gong et al.
Conflict of interest statement
The authors declare that there are no conflicts of interest.
Figures
Similar articles
-
[Clinical results of recombinant human endostatin combined with chemoradiotherapy for locally advanced nasopharyngeal carcinoma].Zhonghua Zhong Liu Za Zhi. 2015 Feb;37(2):128-32. Zhonghua Zhong Liu Za Zhi. 2015. PMID: 25975690 Chinese.
-
A phase II multicenter randomized controlled trial to compare standard chemoradiation with or without recombinant human endostatin injection (Endostar) therapy for the treatment of locally advanced nasopharyngeal carcinoma: Long-term outcomes update.Curr Probl Cancer. 2020 Feb;44(1):100492. doi: 10.1016/j.currproblcancer.2019.06.007. Epub 2019 Jul 2. Curr Probl Cancer. 2020. PMID: 32035692 Clinical Trial.
-
[Induction chemotherapy with docetaxel plus cisplatin (TP regimen) followed by concurrent chemoradiotherapy with TP regimen versus cisplatin in treating locally advanced nasopharyngeal carcinoma].Ai Zheng. 2009 Mar;28(3):279-85. Ai Zheng. 2009. PMID: 19619443 Clinical Trial. Chinese.
-
Meta-Analysis on Induction Chemotherapy in Locally Advanced Nasopharyngeal Carcinoma.Oncologist. 2021 Jan;26(1):e130-e141. doi: 10.1002/ONCO.13520. Epub 2020 Oct 1. Oncologist. 2021. PMID: 32924198 Free PMC article.
-
Induction treatment prior to chemoradiotherapy in nasopharyngeal carcinoma: triplet or doublet chemotherapy?Anticancer Drugs. 2020 Feb;31(2):97-100. doi: 10.1097/CAD.0000000000000867. Anticancer Drugs. 2020. PMID: 31815764 Review.
Cited by
-
Anti-angiogenesis agents plus chemoradiotherapy for locally advanced nasopharyngeal cancer: a systematic review and meta-analysis.Eur Arch Otorhinolaryngol. 2024 Aug;281(8):3929-3941. doi: 10.1007/s00405-024-08545-9. Epub 2024 Apr 16. Eur Arch Otorhinolaryngol. 2024. PMID: 38625559
-
Galunisertib promotes bevacizumab-induced vascular normalization in nasopharyngeal carcinoma: Multi-parameter MRI evaluation.Mol Ther Oncol. 2024 Aug 8;32(3):200858. doi: 10.1016/j.omton.2024.200858. eCollection 2024 Sep 19. Mol Ther Oncol. 2024. PMID: 39280586 Free PMC article.
-
Retracted: The Treatment Combining Antiangiogenesis with Chemoradiotherapy Impinges on the Peripheral Circulation Vascular Endothelial Cells and Therapeutic Effect in the Patients with Locally Advanced Nasopharyngeal Carcinoma.Biomed Res Int. 2024 Mar 20;2024:9842547. doi: 10.1155/2024/9842547. eCollection 2024. Biomed Res Int. 2024. PMID: 38550099 Free PMC article.
-
Angiogenesis in nasopharyngeal carcinoma: insights, imaging, and therapeutic strategies.Front Oncol. 2024 May 28;14:1331064. doi: 10.3389/fonc.2024.1331064. eCollection 2024. Front Oncol. 2024. PMID: 38863627 Free PMC article. Review.
References
-
- Folkman J. Tumor angiogenesis: therapeutic implications. The New England Journal of Medicine . 1971;285(21):1182–1186. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources